Ublituximab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Ublituximab
Accession Number
DB11850
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Ublituximab has been used in trials studying the treatment of B-cell Lymphoma, Neuromyelitis Optica, Mantle Cell Lymphoma, Non-Hodgkins Lymphoma, and Marginal Zone Lymphoma, among others.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
Categories
UNII
U59UGK3IPC
CAS number
1174014-05-1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Ublituximab.
AbituzumabThe risk or severity of adverse effects can be increased when Ublituximab is combined with Abituzumab.
AbrilumabThe risk or severity of adverse effects can be increased when Ublituximab is combined with Abrilumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Ublituximab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Ublituximab.
AducanumabThe risk or severity of adverse effects can be increased when Ublituximab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Ublituximab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Ublituximab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Ublituximab.
AmatuximabThe risk or severity of adverse effects can be increased when Ublituximab is combined with Amatuximab.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911248
Wikipedia
Ublituximab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentChronic Lymphocytic Leukaemia (CLL)1
1CompletedTreatmentNeuromyelitis Optica / Neuromyelitis Optica Spectrum Disorder1
1RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Non Hodgkin Lymphoma (NHL)1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, B-Cell / Marginal Zone Lymphoma / Non-Hodgkin's Lymphoma (NHL) / Primary Central Nervous System Lymphoma (PCNSL) / Small Lymphocytic Lymphoma (SLL) / Waldenström's Macroglobulinemia (WM)1
1, 2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Mantle Cell Lymphoma (MCL)1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)1
1, 2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Richter's Syndrome1
2Active Not RecruitingTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentDisseminated Sclerosis1
2Enrolling by InvitationTreatmentChronic Lymphocytic Leukaemia (CLL)1
2Enrolling by InvitationTreatmentChronic Lymphocytic Leukaemia (CLL) / Non Hodgkin Lymphoma (NHL)1
2RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
2RecruitingTreatmentFollicular Lymphoma (FL) / Small Lymphocytic Lymphoma (SLL)1
2, 3RecruitingTreatmentFollicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma / Small Lymphocytic Lymphoma (SLL)1
3Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL)2
3Active Not RecruitingTreatmentRelapsing Multiple Sclerosis (RMS)2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 14:53 / Updated on September 02, 2019 19:32